Skip to main content

Table 2 Outcome data

From: Implementation of genotype-guided dosing of warfarin with point-of-care genetic testing in three UK clinics: a matched cohort study

Outcome Implementation group Control group Dashboard data Combined control group Implementation vs combined control Implementation vs control group
n = 119 n = 93 n = 640 n = 733 Comparison (95% CI) p value Comparison (95% CI) p value
Percentage time in therapeutic range—mean % (sd) 62.74 (20.57) 54.86 (20.70) 55.31 (23.10) 55.25 (22.79) 7.49 (3.41 to 11.57)1 0.0004 6 7.89 (2.25 to 13.52)3 0.006 6
INR ≥ 4 during first week—n (%) 2 (1.68) 10 (10.75) 44 (6.88) 54 (7.37) 0.21 (0.05 to 0.89)2 0.03 7 0.14 (0.03 to 0.66)4 0.01 7
INR < 2 during first week—n (%) 91 (76.47) 70 (75.27) 338 (52.81) 408 (55.66) 2.59 (1.65 to 4.05)2 < 0.0001 7 1.07 (0.57 to 2.01)4 0.84 7
Number of clinic visits—median (IQR) 10 (8–11) 10 (9–12) 9 (8–13) 10 (8–12) 0.49 8 0.18 8
Number of adverse events 19 0 N/A N/A N/A N/A N/A N/A
  1. 1Difference in percentage points between implementation and combined control group (implementation minus control)
  2. 2Odds ratio for implementation group vs combined control group
  3. 3Difference in percentage points between implementation and control group (implementation minus control)
  4. 4Odds ratio for implementation group vs control group
  5. 6p value from Student’s t-test
  6. 7p value from Pearson’s chi-square test with Yates’ continuity correction
  7. 8p value from Mann-Whitney U test
  8. 9One patient stopped warfarin due to bladder bleed